Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Open Access
- 30 September 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 54 (1), 44-50
- https://doi.org/10.1007/s00125-010-1922-6
Abstract
Aims/hypothesis To assess the effect of an angiotensin receptor blocker (ARB) on serum potassium and the effect of a serum potassium change on renal outcomes in patients with type 2 diabetes and nephropathy. Methods We performed a post hoc analysis in patients with type 2 diabetes participating in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Renal outcomes were defined as a composite of doubling of serum creatinine or end-stage renal disease. Results At month 6, 259 (38.4%) and 73 (10.8%) patients in the losartan group and 151 (22.8%) and 34 (5.1%) patients in the placebo group had serum potassium ≥5.0 mmol/l and ≥5.5 mmol/l, (p < 0.001), respectively. Losartan was an independent predictor for serum potassium ≥5.0 mmol/l at month 6 (OR 2.8; 95% CI 2.0–3.9). Serum potassium at month 6 ≥ 5.0 mmol/l was in turn associated with increased risk for renal events (HR 1.22; 95% CI 1.00–1.50), independent of other risk factors. Adjustment of the overall treatment effects for serum potassium augmented losartan’s renoprotective effect from 21% (6–34%) to 35% (20–48%), suggesting that the renoprotective effects of losartan are offset by its effect on serum potassium. Conclusions/interpretation In this study, we found that treatment with the ARB losartan is associated with a high risk of increased serum potassium levels, which is in turn associated with an increased risk of renal outcomes in patients with diabetes and nephropathy. Whether additional management of high serum potassium would further increase the renal protective properties of losartan is an important clinical question.Keywords
This publication has 27 references indexed in Scilit:
- Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney diseaseNephrology Dialysis Transplantation, 2009
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney DiseaseArchives of Internal Medicine, 2009
- Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit.Circulation, 2008
- Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)Cell Metabolism, 2008
- Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors AnalysisThe American Journal of the Medical Sciences, 2008
- Normal Reference Laboratory ValuesNew England Journal of Medicine, 2004
- The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL StudyKidney International, 2003
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)Journal of the Renin-Angiotensin-Aldosterone System, 2000
- Pathophysiology of low renin syndromes: Sites of renal renin secretory impairment and prorenin overexpressionKidney International, 1993
- Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in manJournal of Clinical Endocrinology & Metabolism, 1992